Mass. gets $2.1M in drug settlement
BOSTON — Massachusetts is getting more than $2.1 million to settle claims that British drug maker GlaxoSmithKline LLC deceptively promoted the diabetes drug Avandia.
The payment is part of a $90 million settlement between GlaxoSmithKline and attorneys general from 38 different states.
Attorney General Martha Coakley’s office says the Massachusetts share of the settlement will mostly fund programs to lower health care costs for residents, combat unlawful marketing practices in the health care market or benefit consumers.
Attorney generals say GlaxoSmithKline misrepresented Avandia’s cardiovascular risks and safety profile. The agreement requires the company to reform its marketing practices and to publicize information about any company-sponsored clinical trials on its diabetes drugs GlaxoSmithKline doesn’t admit any wrongdoing.
as House speaker
CONCORD — New Hampshire’s newly elected Democratic representatives nominated former House speaker and current House minority leader Terie Norelli of Portsmouth as their speaker for the next two years.
Democrats regained the majority in the election this month with a 221-179 edge over Republicans, though recounts could change the split slightly. The Legislature was set to meet Dec. 5 to organize and elect leaders. If House Democrats stick together, their nominee, Norelli, will become speaker.
$5M awarded in NH medical misdiagnosis
EXETER — A New Hampshire jury has awarded $5 million to an Epping woman in a medical misdiagnosis case.
The Portsmouth Herald says a Rockingham County jury issued a verdict Thursday in favor of Noel and Adam Jodoin in a medical negligence case against Dr. Ellen Johnson.
A former radiologist from Advanced Diagnostic Imaging in Exeter, Johnson was ruled at fault for the misdiagnosis in a case involving Noel Jodoin in August 2007. The verdict came after a two-week trial and three hours of jury deliberation.
The suit said that after Jodoin had a CT scan following a long and severe headache, Johnson failed to find abnormalities of clinical significance.